ELTP · CIK 0001053369 · FY2026 live · 2026-03-31
ELITE PHARMACEUTICALS INC /NV/
View as
Model
Classic Z
FY2026
3.81
Zone
Safe
Prior
—
Market DD
—
1y PD
—
3.81
Z″ 7.73
Score 3.81 · distress below 1.80, grey to 2.99, safe at 3.00 and above.
Classic Z factor contributions
X1 Working capital / assets
Short-term liquidity versus the size of the balance sheet.
0.681.2 × = 0.82X2 Retained earnings / assets
Cushion from years of profits. Share buybacks can push this negative at otherwise healthy firms.
−0.551.4 × = −0.77X3 EBIT / assets
Operating return on assets. Highest weight in the original model.
0.363.3 × = 1.17X4 Book equity / liabilities
Book equity versus the liability stack. Mega-caps often look greyer here than they would if X4 used market cap.
2.510.6 × = 1.51X5 Sales / assets
Asset turnover — how much revenue the asset base supports.
1.081 × = 1.08
Five-year path
Need two annual 10-Ks to draw a path. The desk will pull this issuer’s filings.
Meridian Rank
89.27
0–100 · Classic Z family
Book standing
86
Year change
—
Market PD
—
O-score
98
Events on this name
Same published rows as Today.
Approaching grey
watch · 41
- Live score: — → 3.81
- Cut: — → 1.80
Overview
rule-v1
ELITE PHARMACEUTICALS INC /NV/ is on classic Z at 3.81 (safe) for FY2026, from an SEC 10-K. Book equity / liabilities is the line that sets the print; EBIT / assets is the runner-up. This is the first live year on the desk. No market tape loaded. Classic Z was fit on manufacturers. Buybacks can send retained earnings negative at otherwise healthy issuers. X4 is book equity.
Book screen Safe; market PD —. Market PD has not been priced on this name.
Market DD · naive Merton
No market tape yet.
Pull a year of closes (Yahoo, Nasdaq if Yahoo is limited) and size equity from Nasdaq cap or EDGAR shares. Distance-to-default and 1-year PD stay blank until then.
Sector peers
Closest Classic Z scores · 87th percentile in Healthcare.
Filing line items
Current assets
$112M
Total assets
$138M
Current liabilities
$17M
Total liabilities
$39M
Working capital
$95M
Retained earnings
−$76M
EBIT
$49M
Total sales
$149M
Book equity
$99M
Accession 0001493152-26-031070. Live rank is the latest 10-K on EDGAR (FY2026, period 2026-03-31). Classic Z is the live score. View as is a display overlay. X4 is book equity. Pulled 13 Sept 2026.